Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis

Multitarget anti-Alzheimer agents are the focus of very intensive research. Through a comprehensive bibliometric analysis of the publications in the period 1990–2020, we have identified trends and potential gaps that might guide future directions. We found that: (i) the number of publications boomed...

Descripción completa

Detalles Bibliográficos
Autores: Pérez-Areales, F. Javier, Sampietro, A., Martínez, P., Arce, E. M., Galdeano, Carles, Muñoz-Torrero, Diego
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/288622
Acceso en línea:http://hdl.handle.net/10261/288622
Access Level:acceso abierto
Palabra clave:multifactorial diseases
Alzheimer’s disease
polypharmacology
multitarget drugs
hybrids
target combinations
multitarget drug design
Animal models
id ES_dd373dd9d96ef4fc45a7ae3320aca430
oai_identifier_str oai:digital.csic.es:10261/288622
network_acronym_str ES
network_name_str España
repository_id_str
spelling Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric AnalysisPérez-Areales, F. JavierSampietro, A.Martínez, P.Arce, E. M.Galdeano, CarlesMuñoz-Torrero, Diegomultifactorial diseasesAlzheimer’s diseasepolypharmacologymultitarget drugshybridstarget combinationsmultitarget drug designAnimal modelsMultitarget anti-Alzheimer agents are the focus of very intensive research. Through a comprehensive bibliometric analysis of the publications in the period 1990–2020, we have identified trends and potential gaps that might guide future directions. We found that: (i) the number of publications boomed by 2011 and continued ascending in 2020; (ii) the linked-pharmacophore strategy was preferred over design approaches based on fusing or merging pharmacophores or privileged structures; (iii) a significant number of in vivo studies, mainly using the scopolamine-induced amnesia mouse model, have been performed, especially since 2017; (iv) China, Italy and Spain are the countries with the largest total number of publications on this topic, whereas Portugal, Spain and Italy are the countries in whose scientific communities this topic has generated greatest interest; (v) acetylcholinesterase, β-amyloid aggregation, oxidative stress, butyrylcholinesterase, and biometal chelation and the binary combinations thereof have been the most commonly pursued, while combinations based on other key targets, such as tau aggregation, glycogen synthase kinase-3β, NMDA receptors, and more than 70 other targets have been only marginally considered. These results might allow us to spot new design opportunities based on innovative target combinations to expand and diversify the repertoire of multitarget drug candidates and increase the likelihood of finding effective therapies for this devastating disease.This research was funded by the grants PID2020-118127RB-I00 and RTI2018-096429-B-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, and 2017SGR106 and 2019LLAV00017 from AGAURMolecular Diversity Preservation InternationalMinisterio de Ciencia e Innovación (España)Agencia Estatal de Investigación (España)European CommissionAgència de Gestió d'Ajuts Universitaris i de RecercaConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2023202320222023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/288622reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-118127RB-I00info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-096429-B-I00http://dx.doi.org/10.3390/ph15050545Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2886222026-05-22T06:33:51Z
dc.title.none.fl_str_mv Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
title Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
spellingShingle Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
Pérez-Areales, F. Javier
multifactorial diseases
Alzheimer’s disease
polypharmacology
multitarget drugs
hybrids
target combinations
multitarget drug design
Animal models
title_short Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
title_full Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
title_fullStr Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
title_full_unstemmed Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
title_sort Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
dc.creator.none.fl_str_mv Pérez-Areales, F. Javier
Sampietro, A.
Martínez, P.
Arce, E. M.
Galdeano, Carles
Muñoz-Torrero, Diego
author Pérez-Areales, F. Javier
author_facet Pérez-Areales, F. Javier
Sampietro, A.
Martínez, P.
Arce, E. M.
Galdeano, Carles
Muñoz-Torrero, Diego
author_role author
author2 Sampietro, A.
Martínez, P.
Arce, E. M.
Galdeano, Carles
Muñoz-Torrero, Diego
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Ciencia e Innovación (España)
Agencia Estatal de Investigación (España)
European Commission
Agència de Gestió d'Ajuts Universitaris i de Recerca
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv multifactorial diseases
Alzheimer’s disease
polypharmacology
multitarget drugs
hybrids
target combinations
multitarget drug design
Animal models
topic multifactorial diseases
Alzheimer’s disease
polypharmacology
multitarget drugs
hybrids
target combinations
multitarget drug design
Animal models
description Multitarget anti-Alzheimer agents are the focus of very intensive research. Through a comprehensive bibliometric analysis of the publications in the period 1990–2020, we have identified trends and potential gaps that might guide future directions. We found that: (i) the number of publications boomed by 2011 and continued ascending in 2020; (ii) the linked-pharmacophore strategy was preferred over design approaches based on fusing or merging pharmacophores or privileged structures; (iii) a significant number of in vivo studies, mainly using the scopolamine-induced amnesia mouse model, have been performed, especially since 2017; (iv) China, Italy and Spain are the countries with the largest total number of publications on this topic, whereas Portugal, Spain and Italy are the countries in whose scientific communities this topic has generated greatest interest; (v) acetylcholinesterase, β-amyloid aggregation, oxidative stress, butyrylcholinesterase, and biometal chelation and the binary combinations thereof have been the most commonly pursued, while combinations based on other key targets, such as tau aggregation, glycogen synthase kinase-3β, NMDA receptors, and more than 70 other targets have been only marginally considered. These results might allow us to spot new design opportunities based on innovative target combinations to expand and diversify the repertoire of multitarget drug candidates and increase the likelihood of finding effective therapies for this devastating disease.
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/288622
url http://hdl.handle.net/10261/288622
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-118127RB-I00
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-096429-B-I00
http://dx.doi.org/10.3390/ph15050545
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Molecular Diversity Preservation International
publisher.none.fl_str_mv Molecular Diversity Preservation International
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421840286351360
score 15,811543

Similares en LA Referencia